306 related articles for article (PubMed ID: 36270461)
1. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Haanen J; Obeid M; Spain L; Carbonnel F; Wang Y; Robert C; Lyon AR; Wick W; Kostine M; Peters S; Jordan K; Larkin J;
Ann Oncol; 2022 Dec; 33(12):1217-1238. PubMed ID: 36270461
[No Abstract] [Full Text] [Related]
2. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma.
Powles T; Albiges L; Bex A; Grünwald V; Porta C; Procopio G; Schmidinger M; Suárez C; de Velasco G;
Ann Oncol; 2021 Dec; 32(12):1511-1519. PubMed ID: 34597799
[No Abstract] [Full Text] [Related]
3. Discordance between recommended and delivered therapies for immunotherapy-associated cutaneous toxicities in pediatric populations.
Thompson LL; Chang MS; McCormack L; Polyakov NJ; Song H; Huang JT; Chen ST
Pediatr Blood Cancer; 2020 Oct; 67(10):e28653. PubMed ID: 32798306
[No Abstract] [Full Text] [Related]
4. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Hendriks LE; Kerr KM; Menis J; Mok TS; Nestle U; Passaro A; Peters S; Planchard D; Smit EF; Solomon BJ; Veronesi G; Reck M;
Ann Oncol; 2023 Apr; 34(4):358-376. PubMed ID: 36669645
[No Abstract] [Full Text] [Related]
5. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
Thompson JA; Schneider BJ; Brahmer J; Achufusi A; Armand P; Berkenstock MK; Bhatia S; Budde LE; Chokshi S; Davies M; Elshoury A; Gesthalter Y; Hegde A; Jain M; Kaffenberger BH; Lechner MG; Li T; Marr A; McGettigan S; McPherson J; Medina T; Mohindra NA; Olszanski AJ; Oluwole O; Patel SP; Patil P; Reddy S; Ryder M; Santomasso B; Shofer S; Sosman JA; Wang Y; Zaha VG; Lyons M; Dwyer M; Hang L
J Natl Compr Canc Netw; 2022 Apr; 20(4):387-405. PubMed ID: 35390769
[TBL] [Abstract][Full Text] [Related]
6. Toxicities from immunotherapy: From clinical trials to real-world clinical practice.
Riveiro-Barciela M; Trallero-Araguás E; Martínez-Valle F; ;
Med Clin (Barc); 2020 Dec; 155(12):541-547. PubMed ID: 32868034
[TBL] [Abstract][Full Text] [Related]
7. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Haanen JBAG; Carbonnel F; Robert C; Kerr KM; Peters S; Larkin J; Jordan K;
Ann Oncol; 2018 Oct; 29(Suppl 4):iv264-iv266. PubMed ID: 29917046
[No Abstract] [Full Text] [Related]
8. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
9. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Obermannová R; Alsina M; Cervantes A; Leong T; Lordick F; Nilsson M; van Grieken NCT; Vogel A; Smyth EC;
Ann Oncol; 2022 Oct; 33(10):992-1004. PubMed ID: 35914638
[No Abstract] [Full Text] [Related]
10. Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy.
Rashdan S; Minna JD; Gerber DE
Lancet Respir Med; 2018 Jun; 6(6):472-478. PubMed ID: 29856320
[TBL] [Abstract][Full Text] [Related]
11. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Oaknin A; Bosse TJ; Creutzberg CL; Giornelli G; Harter P; Joly F; Lorusso D; Marth C; Makker V; Mirza MR; Ledermann JA; Colombo N;
Ann Oncol; 2022 Sep; 33(9):860-877. PubMed ID: 35690222
[No Abstract] [Full Text] [Related]
12. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Lordick F; Carneiro F; Cascinu S; Fleitas T; Haustermans K; Piessen G; Vogel A; Smyth EC;
Ann Oncol; 2022 Oct; 33(10):1005-1020. PubMed ID: 35914639
[No Abstract] [Full Text] [Related]
13. Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician.
Hansen ED; Wang X; Case AA; Puzanov I; Smith T
J Pain Symptom Manage; 2018 Sep; 56(3):460-472. PubMed ID: 29792979
[TBL] [Abstract][Full Text] [Related]
14. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities.
Cooksley T; Girotra M; Ginex P; Gordon RA; Anderson R; Blidner A; Choi J; Dougan M; Glezerman I; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6175-6181. PubMed ID: 32856213
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
Gullo G; Rubatto M; Fava P; Brizio M; Tonella L; Ribero S; Medri M; Avallone G; Mastorino L; Fierro MT; Stanganelli I; Quaglino P
Dermatol Ther; 2022 Jun; 35(6):e15492. PubMed ID: 35384181
[TBL] [Abstract][Full Text] [Related]
16. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Krämer A; Bochtler T; Pauli C; Baciarello G; Delorme S; Hemminki K; Mileshkin L; Moch H; Oien K; Olivier T; Patrikidou A; Wasan H; Zarkavelis G; Pentheroudakis G; Fizazi K;
Ann Oncol; 2023 Mar; 34(3):228-246. PubMed ID: 36563965
[No Abstract] [Full Text] [Related]
17. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.
Maus MV; Alexander S; Bishop MR; Brudno JN; Callahan C; Davila ML; Diamonte C; Dietrich J; Fitzgerald JC; Frigault MJ; Fry TJ; Holter-Chakrabarty JL; Komanduri KV; Lee DW; Locke FL; Maude SL; McCarthy PL; Mead E; Neelapu SS; Neilan TG; Santomasso BD; Shpall EJ; Teachey DT; Turtle CJ; Whitehead T; Grupp SA
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335028
[TBL] [Abstract][Full Text] [Related]
18. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Hendriks LE; Kerr KM; Menis J; Mok TS; Nestle U; Passaro A; Peters S; Planchard D; Smit EF; Solomon BJ; Veronesi G; Reck M;
Ann Oncol; 2023 Apr; 34(4):339-357. PubMed ID: 36872130
[No Abstract] [Full Text] [Related]
19. Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy.
Hsu ML; Murray JC; Psoter KJ; Zhang J; Barasa D; Brahmer JR; Ettinger DS; Forde PM; Hann CL; Lam VK; Levy B; Marrone KA; Patel T; Peterson V; Sagorsky S; Turner M; Anagnostou V; Naidoo J; Feliciano JL
Oncologist; 2022 Nov; 27(11):971-981. PubMed ID: 35972337
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary Toxicities of Immunotherapy.
Altan M; Zhong L; Shannon VR; Sheshadri A
Adv Exp Med Biol; 2021; 1342():357-375. PubMed ID: 34972974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
